Showing results (331-340 of 367) with videos related to

Sort By:
Pageof 37
Blood|February 3, 2025
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapyMarcos Garcia-Lacarte, Sara C Grijalba, Javier Melchor Sánchez, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Science Translational Medicine|March 6, 2024
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humansAngela A Wang, Felix Luessi, Tradite Neziraj, et al.
Blood|March 3, 2010
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityEkkehard Mössner, Peter Brünker, Samuel Moser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
Molecular Cancer Therapeutics|April 3, 2016
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell ApoptosisPeter Brünker, Katharina Wartha, Thomas Friess, et al.
Cancer Research Communications|June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlPatrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Nature Communications|November 18, 2024
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumorsMacarena Román Alonso, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid TumorsMarina Bacac, Tanja Fauti, Johannes Sam, et al.
Pageof 37